BC Platforms has entered into a strategic partnership with OmicsBank to expand access to large-scale, research-ready real-world and multi-omics healthcare data from India and the United Arab Emirates, strengthening the representation of under-served populations in global life sciences research.
Through the collaboration, BC Platforms has expanded its global data partner network to include more than 12 million patient lives from India and approximately 500,000 patient lives from the UAE, increasing its overall patient catchment to over 187 million worldwide. The partnership also includes plans to further scale datasets across India and extend coverage to additional emerging markets, including Saudi Arabia, Taiwan, the Philippines, and Malaysia, as OmicsBank continues to grow its hospital and diagnostic laboratory partnerships.
OmicsBank provides access to large-scale longitudinal datasets spanning electronic medical records, pathology slides, medical imaging, genomic sequencing data, and associated biospecimens. These datasets can be delivered as modular collections for targeted research needs or as comprehensive longitudinal cohorts, supporting advanced analytics and the development, training, and validation of multimodal artificial intelligence models in healthcare.
The datasets will be integrated into BC Platforms’ agentic AI data mastering platform, BC Unify, and made available through BC Mosaic, which enables federated trusted research environments, and BC Catalyst, which supports insights generation and predictive analytics. This infrastructure is designed to support the full drug development lifecycle, from early discovery and feasibility assessment to clinical development, real-world evidence generation, post-market analysis, and large-scale AI model training on complex, multi-modal healthcare data.
The partnership addresses a longstanding gap in global biomedical research, where South Asian populations remain significantly under-represented in large-scale genomic and real-world data studies despite India accounting for nearly one-fifth of the global population. Limited access to diverse datasets has constrained the generalizability of findings and slowed the adoption of precision medicine approaches across non-Western populations.
India’s genetic diversity and growing burden of non-communicable diseases, including cardiovascular disease, diabetes, and cancer, position the country as a critical market for clinical research and drug development. By enabling secure, scalable access to research-ready datasets from India and the UAE, the collaboration aims to support more representative cohort selection, improved feasibility assessments, reduced research bias, and more cost-efficient global drug development strategies.
